T he FDA approved a new monthly paliperidone palmitate (Erzofri) extended-release injectable suspension for treating schizophrenia in adults, Luye Pharma announced.

Among adults with schizophrenia or schizoaffective disorder, treatment with the newer, more costly antipsychotic paliperidone palmitate, compared with the older antipsychotic haloperidol decanoate ...

The FDA has approved a long-acting, once-monthly formulation of paliperidone palmitate injection for the acute and maintenance treatment of schizophrenia in adults.

Among adults with schizophrenia or schizoaffective disorder, treatment with the newer, more costly antipsychotic paliperidone palmitate, compared with the older antipsychotic haloperidol decanoate ...

ERZOFRI, administered once a month, is the first patented paliperidone palmitate long-acting injection developed in China to get approved in the U.S.

The 335 patent relates to dosing regimens for paliperidone palmitate depot (long-acting) formulations for the treatment of schizophrenia.

Erzofri (paliperidone palmitate extended-release injectable suspension) is now available for treating schizophrenia and schizoaffective disorder in adults.

Invega Sustenna (paliperidone palmitate) was approved by the FDA in July 2009 as the first once-monthly atypical long-acting injection to treat. Late last year the FDA approved Invega Sustenna for ...

Luye Pharma Group today announced that ERZOFRI® (paliperidone palmitate) extended-release injectable suspension is now available for commercial sale in the U.S. for the treatment of adults with ...

Investigator evaluations of injection-site pain, swelling, redness, and induration, as well as patient evaluations of injection-site pain during this study, suggest that paliperidone palmitate is ...